Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Perspective Therapeutics (CATX) EBIT Margin (2016 - 2025)

Perspective Therapeutics (CATX) has disclosed EBIT Margin for 16 consecutive years, with 189676.19% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 20432896.0% to 189676.19% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 22355.12% through Dec 2025, down 1589096.0% year-over-year, with the annual reading at 22355.12% for FY2025, 1589096.0% down from the prior year.
  • EBIT Margin hit 189676.19% in Q4 2025 for Perspective Therapeutics, up from 19347.92% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 189676.19% in Q4 2025 to a low of 19347.92% in Q3 2025.
  • Historically, EBIT Margin has averaged 6125.93% across 5 years, with a median of 446.22% in 2023.
  • Biggest five-year swings in EBIT Margin: plummeted -1495963bps in 2024 and later skyrocketed 20432896bps in 2025.
  • Year by year, EBIT Margin stood at 58.06% in 2021, then crashed by -322bps to 245.08% in 2022, then skyrocketed by 225bps to 306.86% in 2023, then crashed by -4875bps to 14652.77% in 2024, then soared by 1394bps to 189676.19% in 2025.
  • Business Quant data shows EBIT Margin for CATX at 189676.19% in Q4 2025, 19347.92% in Q3 2025, and 14057.89% in Q2 2025.